^
Association details:
Evidence:
Evidence Level:
Resistant: D – Preclinical
New
Title:

FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib

Excerpt:
We showed that FGF19, when overexpressed, inhibited the effect of sorafenib on ROS generation and apoptosis in HCC.
DOI:
10.1186/s13046-016-0478-9